EZH2 and T-cell leukemia: To test this hypothesis, we first exposed Jurkat cells, a T-cell leukemia line, to the p38 MAP kinase inhibitor (10 nM) (Catalog number 506126, Calbiochem Co., La Jolla, CA, USA), which resulted in a decrease in the level of p-p38 and a significant increase in the level of Ezh2 (Figure 4A).